Edwards Lifesciences Corporation (EW) Stock Price: $90.78+1.06 (+1.18%)
At close: Jun 26, 2026, 4:00 PM ET
The closing share price for Edwards Lifesciences Corporation (EW) stock was $90.78 for Friday, June 26, 2026, up 1.18% on the day.
Longer view (total return, dividends reinvested): past 12 months +17.7% · 3-year avg +0.5%/yr · 5-year avg -2.6%/yr
EW Price Chart
EW Key Metrics
See All MetricsLAST CLOSE PRICE
$90.78
52-WEEK RANGE
$72.30 - $92.46
BETA
0.87
% FROM 52W HIGH
-1.82%
MARKET CAP
$52.27B
DIVIDEND YIELD
N/A
PE RATIO
trailing TTM
48.29
PE RATIO (FWD)
next-FY estimate
26.89
P/B RATIO
5.10
DEBT / EQUITY
0.07
REVENUE TTM
$6.30B
NET INCOME TTM
$1.09B
NET PROFIT MARGIN TTM
17.34%
TTM TOTAL RETURN
+17.68%
3Y TOTAL RETURN
+0.48%
5Y TOTAL RETURN
-2.60%
EW Revenue by Segment
How EW’s revenue breaks down across its reported segments in the latest reported fiscal year.
By product / business (FY 2025)
- Transcatheter Heart Valves$4.49B74.0%
- Surgical Heart Valve Therapy$1.03B17.0%
- Transcatheter Mitral And Tricuspid Therapies$550.60M9.1%
By geography (FY 2025)
- United States$3.54B58.4%
- Europe$1.52B25.0%
- Rest of World$652.30M10.8%
- Japan$354.70M5.8%
EW Earnings Preview
Next Earnings Date
Jul 23, 2026
24 days away
EPS Estimate
0.73
Revenue Est.
$1.70B
Last Quarter Results
EPS
$0.78
vs Estimate
$0.73
Revenue
$1.65B
vs Estimate
$1.60B
EW Analyst Ratings
Consensus Rating
Based on 26 analysts
Average Price Target
$96.92
+6.8% upside
Low
$84.00
Current
$90.78
High
$110.00
EW Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $0.83 | $0.84 | $0.85 | 10 |
| Q2 2027 | $0.83 | $0.84 | $0.85 | 7 |
| Q3 2027 | $0.84 | $0.85 | $0.86 | 7 |
| Q4 2027 | $0.83 | $0.84 | $0.85 | 14 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $3.32 | $3.38 | $3.50 | 16 |
| FY 2028 | $3.70 | $3.80 | $3.90 | 7 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $1.78B | $1.80B | $1.81B | 11 |
| Q2 2027 | $1.83B | $1.85B | $1.87B | 8 |
| Q3 2027 | $1.83B | $1.85B | $1.87B | 8 |
| Q4 2027 | $1.87B | $1.89B | $1.91B | 15 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $7.19B | $7.43B | $7.53B | 22 |
| FY 2028 | $8.16B | $8.18B | $8.19B | 22 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcareEW Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1EW | $52.27B | $90.78 | +1.18% | +17.68% | -2.60% | +10.98% | — |
| 2COR | $55.67B | $286.13 | -0.29% | -2.80% | +20.95% | +16.35% | vs EW |
| 3CAH | $55.72B | $237.92 | +1.35% | +45.32% | +36.05% | +15.40% | vs EW |
| 4BDX | $56.49B | $155.92 | +3.00% | +19.56% | -1.62% | +3.62% | vs EW |
| 5HUM | $46.08B | $383.84 | +2.09% | +62.97% | -1.76% | +8.62% | vs EW |
| 6IDXX | $43.50B | $551.50 | -0.62% | +4.50% | -2.33% | +20.17% | vs EW |
EW Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian